Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cord Blood America, Inc. (CBAI) Announces Successful Treatment Of Diabetes Using Umbilical Cord Blood Stem Cells

|Includes: Cord Blood America, Inc. (CBAI)

A great deal of controversy surrounds stem cell research, especially embryonic stem cell research, but one U.S. company is pioneering noninvasive, noncontroversial stem cell extraction that, so far, is achieving amazing and potentially lifesaving results. Cord Blood America, Inc. announced today that stem cells extracted from umbilical cord blood have been successfully used in the treatment of type 1 diabetes. What this potentially means for type 1 diabetes sufferers is new life and the potential alleviation of a lifelong regimen of insulin shots and closely watched diets with no relief in sight.

USA Today and Medical News Today have reported that stem cells extracted from umbilical cords - taken at birth with no effect or harm to the newborn infant - have been successfully used to "reeducate" the immune system T cells of individuals with type 1 diabetes - rejuvenating pancreatic function and prompting new production of insulin. This has resulted in a reduction of the daily injected insulin these individuals need in order to survive, and these results are giving new hope to diabetes sufferers and researchers everywhere. Even longtime diabetics believed to have no insulin-producing ability experienced increased insulin production after the stem cell treatment.

Furthermore, scientists at the University of Central Florida recently announced that they have successfully transformed umbilical stem cells into other types of cells. This breakthrough could be significant in the treatment of spinal cord injuries, multiple sclerosis and other diseases of the nervous system.

Cord Blood America's research has additionally linked umbilical cord stem cells to potential treatments for cancer, leukemia, immune disorders and other illnesses.

Healthcare market research firm Kalorama Information estimates that markets for stem cell technologies could soon surpass $1 billion.

Cord Blood America's mission is to be the industry's most respected stem cell preservation company. For further information about Cord Blood America, visit corcell.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net